Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
CA 2349865 C · Owner: Johnson, William T. · Inventors: Johnson, William T.; Yakubu-Madus, Fatima Emitsel; Stramm, Lawrence E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1) to , treat non-insulin dependent diabetes mellitus optionally with other , therapies, by improving glycemic control while minimizing side effects such , as heart hypertrophy and elevated fed-state plasma glucose which are , associated with both TZD and GLP-1 monotherapies. Thus the co-administration , of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 6, 2000 and granted August 19, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 6, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 6, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.